New hope for antibody to treat muscular dystrophy – Medical Xpress


Forget Password?
Learn more
share this!
1.3K
19
Share
Email
September 13, 2021
by Marla Paul,
Northwestern Medicine scientists have developed an antibody that they believe can be used to treat muscular dystrophy, findings that were published in Science Translational Medicine.

googletag.cmd.push(function() { googletag.display(‘div-gpt-ad-1450190541376-1’); });

“We believe this can become a therapy for , including the many different forms of muscular dystrophy,” said senior study author Elizabeth McNally, MD, Ph.D., director of the Center for Genetic Medicine and the Elizabeth J. Ward Professor of Genetic Medicine. “Given the success with so many other in treating chronic human diseases like and psoriasis, we are very optimistic this antibody can translate into the human disease setting.”
The antibody targets the TGF-beta , a pathway known to be important for regulating scarring (fibrosis). In muscular dystrophy, the muscles become scarred over time, and this antibody helps reduce scarring in the muscles. With this treatment the muscles also became stronger.
The study was conducted in an animal model of muscular dystrophy, and the scientists hope to develop the antibody to treat people, since the pathways are the same in the animal models as they are in people with muscular dystrophy.
About 300,000 people in the U.S. live with muscular dystrophy. There are currently only a small number of treatments for a tiny percentage of patients who have very specific gene mutations. Most patients with muscular dystrophy have no therapeutic options.
The target protein in this case binds the three major forms of TGF-beta, which makes it more effective than other approaches that target single forms of TGF-beta. Many scientists have tried to target TGF-beta to treat disease, but it has been difficult to do this successfully because of the multiple forms and their complicated pathway of action.
The team made an antibody to the that binds all three forms of TGF-beta and stabilizes these proteins so they cannot become active. Too much TGF-beta activity is a major contributor to scarring and weakness in muscular dystrophy.
Alexis Demonbreun, Ph.D., the lead study author and an assistant professor of Pharmacology, selected antibodies to the hinge region of the (called LTBP4), since this hinge is critically important to stabilizing and keeping TGF-beta from being overactive. The hinge is normally cleaved by enzymes to trigger release of TGF-beta. The antibody blocks the cleavage and the activation of the complex.
The next steps in the research are optimizing the antibody sequence to improve its activity and so that it can be produced in larger quantities. Once that is done, the full safety studies are required before launching a clinical trial.


Explore further

Novel muscular dystrophy gene connects to a key biological pathway


More information: Alexis R. Demonbreun et al, Anti-latent TGFβ binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy, Science Translational Medicine (2021). DOI: 10.1126/scitranslmed.abf0376

Journal information: Science Translational Medicine

Citation: New hope for antibody to treat muscular dystrophy (2021, September 13) retrieved 16 September 2021 from https://medicalxpress.com/news/2021-09-antibody-muscular-dystrophy.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further
Facebook
Twitter
Email
Feedback to editors
21 hours ago
0
Sep 13, 2021
2
Sep 13, 2021
2
Sep 13, 2021
0
Sep 10, 2021
0
54 minutes ago
54 minutes ago
2 hours ago
13 hours ago
13 hours ago
14 hours ago
14 hours ago
Apr 15, 2021
May 30, 2019
Jan 31, 2019
Sep 14, 2014
Oct 09, 2020
Jun 30, 2020
54 minutes ago
17 hours ago
22 hours ago
21 hours ago
13 hours ago
16 hours ago
Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use our contact form. For general feedback, use the public comments section below (please adhere to guidelines).
Please select the most appropriate category to facilitate processing of your request
Thank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Your email address is used only to let the recipient know who sent the email. Neither your address nor the recipient’s address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.

Get weekly and/or daily updates delivered to your inbox. You can unsubscribe at any time and we’ll never share your details to third parties.
More information Privacy policy
Daily science news on research developments and the latest scientific innovations
The latest engineering, electronics and technology advances
The most comprehensive sci-tech news coverage on the web
This site uses cookies to assist with navigation, analyse your use of our services, collect data for ads personalisation and provide content from third parties. By using our site, you acknowledge that you have read and understand our Privacy Policy and Terms of Use.

source